AR032752A1 - Ureido propionamidas o propionamidas heteroaromaticas trans olefinicas 2,3-di-sustituidas, un proceso para su preparacion, composiciones farmaceuticas que los comprenden y el uso de las mismas para la manufactura de un medicamento como activadores de glucoquinasa - Google Patents
Ureido propionamidas o propionamidas heteroaromaticas trans olefinicas 2,3-di-sustituidas, un proceso para su preparacion, composiciones farmaceuticas que los comprenden y el uso de las mismas para la manufactura de un medicamento como activadores de glucoquinasaInfo
- Publication number
- AR032752A1 AR032752A1 ARP000106608A ARP000106608A AR032752A1 AR 032752 A1 AR032752 A1 AR 032752A1 AR P000106608 A ARP000106608 A AR P000106608A AR P000106608 A ARP000106608 A AR P000106608A AR 032752 A1 AR032752 A1 AR 032752A1
- Authority
- AR
- Argentina
- Prior art keywords
- lower alkyl
- substituted
- ring
- propionamids
- carbon atom
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/46—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylureas
- C07C275/48—Y being a hydrogen or a carbon atom
- C07C275/50—Y being a hydrogen or an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Detergent Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Ureido propionamidas o propionamidas heteroaromáticas trans olefínicas 2,3-di-sustituidas siendo dicha sustitucion en la posicion 2 un grupo fenilo sustituido y en la posicion 3 un anillo cicloalquílico, segun formula (1), en donde R1 y R2 son independientemente hidrogeno, halo, amino, nitro, perfluoro-alquilo inferior, alquilo inferior tio, alquilo inferior sulfonilo, alquilo inferior sulfonil metilo, perfluoro-alquilo inferior sulfonilo, o alquilo inferior sulfinilo; R es -(CH2)m-R3 o alquilo inferior C2-4; R3 es cicloalquilo C3-8, formula (2); R4 es o un anillo heteroaromático de 5 o 6 miembros no sustituido o mono-sustituido conectado a través de un átomo de carbono del anillo al grupo amino mostrado, conteniendo dicho anillo heteroaromático de 5 o 6 miembros de 1 a 2 heteroátomos seleccionados del grupo formado por azufre o nitrogeno, siendo uno de los heteroátomos un nitrogeno adyacente al átomo de carbono del anillo de conexion; es dicho anillo heteroaromático mono-sustituido está mono-sustituido en una posicion de un átomo de carbono del anillo diferente a la adyacente a dicho átomo de carbono de conexion, con un sustituyente seleccionado del grupo formado por halo o formula (3), donde m es 0 o 1; n es 0, 1, 2, 3 o 4; R7 es hidrogeno o alquilo inferior; y delta designa una configuracion trans respecto al doble enlace; o una sal farmacéuticamente aceptable del mismo. Siendo dichas propionamidas activadores de la glucoquinasa; un proceso para su preparacion, composicion farmacéutica que los comprenden y el uso de los mismos para la manufactura de un medicamento, que aumenta la secrecion de insulina en el tratamiento de la diabetes tipo H.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17078399P | 1999-12-15 | 1999-12-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR032752A1 true AR032752A1 (es) | 2003-11-26 |
Family
ID=22621235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000106608A AR032752A1 (es) | 1999-12-15 | 2000-12-13 | Ureido propionamidas o propionamidas heteroaromaticas trans olefinicas 2,3-di-sustituidas, un proceso para su preparacion, composiciones farmaceuticas que los comprenden y el uso de las mismas para la manufactura de un medicamento como activadores de glucoquinasa |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US6353111B1 (es) |
| EP (1) | EP1242397B1 (es) |
| JP (1) | JP3824936B2 (es) |
| KR (1) | KR100502032B1 (es) |
| CN (1) | CN1185219C (es) |
| AR (1) | AR032752A1 (es) |
| AT (1) | ATE305461T1 (es) |
| AU (1) | AU781029B2 (es) |
| CA (1) | CA2392903C (es) |
| CO (1) | CO5050295A1 (es) |
| CZ (1) | CZ20022412A3 (es) |
| DE (1) | DE60022903T2 (es) |
| DK (1) | DK1242397T3 (es) |
| ES (1) | ES2249322T3 (es) |
| GC (1) | GC0000264A (es) |
| HK (1) | HK1054383B (es) |
| HR (1) | HRP20020514A2 (es) |
| HU (1) | HUP0203753A3 (es) |
| IL (2) | IL150083A0 (es) |
| JO (1) | JO2180B1 (es) |
| MA (1) | MA26855A1 (es) |
| MX (1) | MXPA02005874A (es) |
| MY (1) | MY125484A (es) |
| NO (1) | NO323142B1 (es) |
| NZ (1) | NZ518974A (es) |
| PE (1) | PE20011022A1 (es) |
| PL (1) | PL355815A1 (es) |
| RU (1) | RU2245332C2 (es) |
| TW (1) | TWI262916B (es) |
| UY (1) | UY26483A1 (es) |
| WO (1) | WO2001044216A1 (es) |
| YU (1) | YU41402A (es) |
| ZA (1) | ZA200203829B (es) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0102299D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
| SE0102300D0 (sv) * | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
| SE0102764D0 (sv) * | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
| CA2471049A1 (en) | 2001-12-21 | 2003-07-10 | Novo Nordisk A/S | Amide derivatives as gk activators |
| EP1485107A1 (en) | 2002-02-11 | 2004-12-15 | Vertex Pharmaceuticals Incorporated | Phospholipids as caspase inhibitor prodrugs |
| EP1496052B1 (en) | 2002-03-26 | 2009-08-05 | Banyu Pharmaceutical Co., Ltd. | Novel aminobenzamide derivative |
| KR101124245B1 (ko) | 2002-06-27 | 2012-07-02 | 노보 노르디스크 에이/에스 | 치료제로서 아릴 카르보닐 유도체 |
| CA2744893A1 (en) | 2002-06-27 | 2004-01-08 | Novo Nordisk A/S | Aryl carbonyl derivatives as glucokinase activators |
| CN1703408A (zh) * | 2002-10-03 | 2005-11-30 | 诺瓦提斯公司 | 作为葡糖激酶激活剂、可用于治疗ⅱ型糖尿病的取代的(噻唑－2－基)酰胺或磺酰胺 |
| GB0226931D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
| GB0226930D0 (en) * | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
| MY141521A (en) | 2002-12-12 | 2010-05-14 | Hoffmann La Roche | 5-substituted-six-membered heteroaromatic glucokinase activators |
| WO2004063194A1 (en) * | 2003-01-06 | 2004-07-29 | Eli Lilly And Company | Heteroaryl compounds |
| JP4621198B2 (ja) * | 2003-02-11 | 2011-01-26 | プロシディオン・リミテッド | トリ（シクロ）置換アミドグルコキナーゼ活性化化合物 |
| PL378117A1 (pl) * | 2003-02-11 | 2006-03-06 | Prosidion Limited | Tricyklopodstawione związki amidowe |
| KR101196313B1 (ko) | 2004-01-06 | 2012-11-07 | 노보 노르디스크 에이/에스 | 헤테로아릴-유리아 및 글루코키나아제 활성제로서의 그들의사용 |
| US20080280872A1 (en) | 2004-02-18 | 2008-11-13 | Craig Johnstone | Benzamide Derivatives and Their Use as Glucokinase Activating Agents |
| CN101098876A (zh) * | 2004-04-02 | 2008-01-02 | 诺瓦提斯公司 | 噻唑并吡啶衍生物、包含它们的药物形式以及治疗葡糖激酶介导的病症的方法 |
| JP4700684B2 (ja) * | 2004-04-02 | 2011-06-15 | ノバルティス アーゲー | ２型糖尿病の処置に有用なグルコキナーゼアクティベーターとしてのスルホンアミド−チアゾロピリジン誘導体 |
| NZ550567A (en) * | 2004-04-21 | 2010-07-30 | Prosidion Ltd | Tri(cyclo) substituted amide compounds |
| TW200600086A (en) | 2004-06-05 | 2006-01-01 | Astrazeneca Ab | Chemical compound |
| WO2005123132A2 (en) * | 2004-06-17 | 2005-12-29 | Novo Nordisk A/S | Use of liver-selective glucokinase activators |
| KR100890695B1 (ko) * | 2004-08-12 | 2009-03-26 | 프로시디온 리미티드 | 치환된 페닐아세트아미드 및 글루코키나제 활성화제로서의그의 용도 |
| WO2007006760A1 (en) | 2005-07-08 | 2007-01-18 | Novo Nordisk A/S | Dicycloalkyl urea glucokinase activators |
| BRPI0622262A2 (pt) | 2005-07-09 | 2011-08-09 | Astrazeneca Ab | composto, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, processo para a preparação de um composto |
| ES2426345T3 (es) | 2005-07-20 | 2013-10-22 | Eli Lilly And Company | Compuesto unidos en posición 1-amino |
| JP2007063225A (ja) * | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
| RU2008112198A (ru) | 2005-09-29 | 2009-10-10 | Санофи-Авентис (Fr) | Производные фенил-1,2,4-оксадиазолона, способы их получения и их применение в качестве фармацевтических средств |
| GT200600428A (es) * | 2005-09-30 | 2007-05-21 | Compuestos organicos | |
| GT200600429A (es) * | 2005-09-30 | 2007-04-30 | Compuestos organicos | |
| BRPI0618062A2 (pt) * | 2005-11-03 | 2011-08-16 | Prosidion Ltd | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, processo para a preparação de um composto |
| DK1951658T3 (da) | 2005-11-17 | 2012-10-15 | Lilly Co Eli | Glucagonreceptorantagonister, fremstilling og terapeutiske anvendelser |
| JP2009515997A (ja) * | 2005-11-18 | 2009-04-16 | タケダ サン ディエゴ インコーポレイテッド | グルコキナーゼ活性剤 |
| EP2001875A2 (en) | 2006-03-08 | 2008-12-17 | Takeda San Diego, Inc. | Glucokinase activators |
| PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
| ATE522518T1 (de) | 2006-05-31 | 2011-09-15 | Takeda San Diego Inc | Indazol- und isoindolderivate als glucokinaseaktivierende stoffe |
| KR101264820B1 (ko) | 2006-08-24 | 2013-05-22 | 유니버시티 오브 테네시 리서치 파운데이션 | 치환된 아실아닐리드 및 그의 사용 방법 |
| SA07280576B1 (ar) | 2006-10-26 | 2011-06-22 | استرازينيكا ايه بي | مركبات بنزويل أمينو سيكليل غير متجانسة بأعتبارها عوامل منشطة للجلوكوكيناز |
| US7902248B2 (en) * | 2006-12-14 | 2011-03-08 | Hoffmann-La Roche Inc. | Oxime glucokinase activators |
| JP5419706B2 (ja) | 2006-12-20 | 2014-02-19 | タケダ カリフォルニア インコーポレイテッド | グルコキナーゼアクチベーター |
| TW200831081A (en) | 2006-12-25 | 2008-08-01 | Kyorin Seiyaku Kk | Glucokinase activator |
| JP5491871B2 (ja) | 2007-02-28 | 2014-05-14 | アドビナス セラピュティックス プライベート リミテッド | グルコキナーゼ活性化因子としての２，２，２−三置換アセトアミド誘導体、その方法及び薬学的応用 |
| KR20090121376A (ko) * | 2007-03-07 | 2009-11-25 | 교린 세이야꾸 가부시키 가이샤 | 글루코키나아제 활성화 물질 |
| US8173645B2 (en) * | 2007-03-21 | 2012-05-08 | Takeda San Diego, Inc. | Glucokinase activators |
| ATE513830T1 (de) * | 2007-09-21 | 2011-07-15 | Sanofi Aventis | Phenothiazin-derivate mit doppelbindung, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| TW200934772A (en) * | 2008-01-15 | 2009-08-16 | Lilly Co Eli | Crystalline(R)-2-(4-cyclopropanesulphonyl-phenyl)-N-pyrazin-2-yl-3-(tetrahydropyran-4-yl)-propionamide |
| RU2010134411A (ru) | 2008-01-18 | 2012-02-27 | Астеллас Фарма Инк. (Jp) | Фенилацетамидное производное |
| KR101608259B1 (ko) * | 2008-04-28 | 2016-04-01 | 교린 세이야꾸 가부시키 가이샤 | 시클로펜틸아크릴산아미드 유도체 |
| CN102105451B (zh) | 2008-05-16 | 2013-11-13 | 塔克达加利福尼亚股份有限公司 | 葡糖激酶活化剂 |
| US8450494B2 (en) | 2009-06-22 | 2013-05-28 | Cadila Healthcare Limited | Disubstituted benzamide derivatives as glucokinase (GK) activators |
| EP2459554B1 (en) | 2009-07-31 | 2013-09-18 | Cadila Healthcare Limited | Substituted benzamide derivatives as glucokinase (gk) activators |
| KR100970871B1 (ko) * | 2009-11-30 | 2010-07-20 | 케이제이알디 (주) | 바닥재 어셈블리 및 바닥재의 시공방법 |
| TWI471132B (zh) | 2009-12-04 | 2015-02-01 | 大正製藥股份有限公司 | ２－吡啶酮化合物 |
| AU2011235212B2 (en) | 2010-03-31 | 2014-07-31 | The Scripps Research Institute | Reprogramming cells |
| US9969683B2 (en) | 2012-07-13 | 2018-05-15 | Gtx, Inc. | Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS) |
| US9744149B2 (en) | 2012-07-13 | 2017-08-29 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
| US10987334B2 (en) | 2012-07-13 | 2021-04-27 | University Of Tennessee Research Foundation | Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs) |
| US10258596B2 (en) | 2012-07-13 | 2019-04-16 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
| US10314807B2 (en) | 2012-07-13 | 2019-06-11 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
| US9622992B2 (en) | 2012-07-13 | 2017-04-18 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
| KR102238970B1 (ko) | 2012-07-13 | 2021-04-09 | 지티엑스, 인코포레이티드 | 선택적 안드로겐 수용체 조절자(sarms)를 이용한 안드로겐 수용체(ar) 양성 유방암의 치료 방법 |
| EP2921489B1 (en) | 2012-11-13 | 2017-09-06 | Nissan Chemical Industries, Ltd. | 2-pyridone compound |
| GB201714777D0 (en) | 2017-09-14 | 2017-11-01 | Univ London Queen Mary | Agent |
| KR20210020866A (ko) | 2018-06-12 | 2021-02-24 | 브이티브이 테라퓨틱스 엘엘씨 | 인슐린 또는 인슐린 유사체와 조합된 글루코키나제 활성제의 치료적 용도 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8909574D0 (en) | 1989-04-26 | 1989-06-14 | Ici Plc | Chemical process |
| US5169951A (en) | 1990-04-23 | 1992-12-08 | Ciba-Geigy Corporation | Process for preparing nematicidal compositions |
| SI1169312T1 (en) * | 1999-03-29 | 2005-02-28 | F. Hoffmann-La Roche Ag | Glucokinase activators |
-
2000
- 2000-12-01 US US09/727,624 patent/US6353111B1/en not_active Expired - Fee Related
- 2000-12-11 JO JO2000197A patent/JO2180B1/en active
- 2000-12-12 RU RU2002118339/04A patent/RU2245332C2/ru not_active IP Right Cessation
- 2000-12-12 KR KR10-2002-7007709A patent/KR100502032B1/ko not_active IP Right Cessation
- 2000-12-12 PL PL00355815A patent/PL355815A1/xx unknown
- 2000-12-12 IL IL15008300A patent/IL150083A0/xx unknown
- 2000-12-12 PE PE2000001324A patent/PE20011022A1/es not_active Application Discontinuation
- 2000-12-12 AU AU23652/01A patent/AU781029B2/en not_active Ceased
- 2000-12-12 CZ CZ20022412A patent/CZ20022412A3/cs unknown
- 2000-12-12 WO PCT/EP2000/012612 patent/WO2001044216A1/en active IP Right Grant
- 2000-12-12 JP JP2001544706A patent/JP3824936B2/ja not_active Expired - Fee Related
- 2000-12-12 DE DE60022903T patent/DE60022903T2/de not_active Expired - Lifetime
- 2000-12-12 AT AT00987392T patent/ATE305461T1/de not_active IP Right Cessation
- 2000-12-12 YU YU41402A patent/YU41402A/sh unknown
- 2000-12-12 ES ES00987392T patent/ES2249322T3/es not_active Expired - Lifetime
- 2000-12-12 EP EP00987392A patent/EP1242397B1/en not_active Expired - Lifetime
- 2000-12-12 MX MXPA02005874A patent/MXPA02005874A/es active IP Right Grant
- 2000-12-12 HU HU0203753A patent/HUP0203753A3/hu unknown
- 2000-12-12 DK DK00987392T patent/DK1242397T3/da active
- 2000-12-12 CA CA002392903A patent/CA2392903C/en not_active Expired - Fee Related
- 2000-12-12 CN CNB008172943A patent/CN1185219C/zh not_active Expired - Fee Related
- 2000-12-12 NZ NZ518974A patent/NZ518974A/en unknown
- 2000-12-13 MY MYPI20005851A patent/MY125484A/en unknown
- 2000-12-13 GC GCP20001095 patent/GC0000264A/en active
- 2000-12-13 CO CO00094817A patent/CO5050295A1/es unknown
- 2000-12-13 AR ARP000106608A patent/AR032752A1/es active IP Right Grant
- 2000-12-14 UY UY26483A patent/UY26483A1/es not_active Application Discontinuation
- 2000-12-14 TW TW089126672A patent/TWI262916B/zh active
-
2002
- 2002-05-14 ZA ZA200203829A patent/ZA200203829B/en unknown
- 2002-06-06 IL IL150083A patent/IL150083A/en not_active IP Right Cessation
- 2002-06-12 HR HR20020514A patent/HRP20020514A2/hr not_active Application Discontinuation
- 2002-06-14 MA MA26690A patent/MA26855A1/fr unknown
- 2002-06-14 NO NO20022863A patent/NO323142B1/no not_active IP Right Cessation
-
2003
- 2003-09-16 HK HK03106627.5A patent/HK1054383B/zh not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR032752A1 (es) | Ureido propionamidas o propionamidas heteroaromaticas trans olefinicas 2,3-di-sustituidas, un proceso para su preparacion, composiciones farmaceuticas que los comprenden y el uso de las mismas para la manufactura de un medicamento como activadores de glucoquinasa | |
| AR031066A1 (es) | Un compuesto que comprende una amida, un proceso para su preparacion, composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos | |
| AR031718A1 (es) | Tetrazolil-fenil acetamida activadores de glucoquinasa, un proceso para su preparacion, composicion farmaceutica, un proceso para su preparacion y el empleo de dichos compuestos para la preparacion de un medicamento | |
| PE20020056A1 (es) | Fenil amidas para-aril o heteroaril sustituidas como activadores de la glucoquinasa | |
| AR046244A1 (es) | Activadores de glucoquinasa heteroaromaticos de seis miembros 5- sustituidos | |
| AR036659A1 (es) | Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentos | |
| AR032626A1 (es) | Amidas, composiciones farmaceuticas que las comprenden, proceso para preparar dichas composiciones, uso de dichas amidas en la preparacion de medicamentos, y proceso para la preparacion de dichas amidas | |
| YU84791A (sh) | Biciklicni 1-aza-cikloalkalni | |
| CO5580771A2 (es) | Antagonistas ccr5 como agentes terapeuticos | |
| AR030279A1 (es) | Derivados de fenilamida para-amino sustituida activadora de la glucoquinasa, un procedimiento para su preparacion, composiciones farmaceuticas y el empleo de dichos derivados para la preparacion de medicamentos. | |
| HUP0302451A2 (hu) | (Tio)karbamoil-ciklohexán származékok, eljárás előállításukra és ezeket hatóanyagként tartalmazó gyógyszerkészítmények | |
| RU2008142834A (ru) | Модуляция церамидкиназы | |
| ECSP056016A (es) | Nuevos derivados de 2-piridinacarboxamida | |
| AR056321A1 (es) | COMBINACIONES TERAPÉUTICAS PARA EL TRATAMIENTO O LA PREVENCIoN DE TRASTORNOS PSICoTICOS | |
| AR030053A1 (es) | 1h-pirimido [4,5-d] pirimidin-2-onas y sales, composiciones farmaceuticas, uso para la fabricacion de un medicamento y procedimiento para producirlas | |
| AR087046A2 (es) | Compuestos derivados de 4-oxoquinolina | |
| TW200617001A (en) | Novel glucitol derivative, its prodrug, their salt and diabetic therapeutic agent containing the same | |
| UY28132A1 (es) | Derivados de pirrolopirimidina | |
| PE20050090A1 (es) | Indol-3-carboxamidas como activadores de glocoquinasa | |
| AR037534A1 (es) | Derivado de adamantano, su uso en la fabricacion de un medicamento para usar en terapia, composicion farmaceutica, proceso para la preparacion de dicho compuesto y dicha composicion y compuestos intermediarios | |
| ES2213007T3 (es) | Derivados de 4,5-diaril-3(2h)-furanona como inhibidores de la ciclooxigenasa-2. | |
| AR019789A2 (es) | Compuestos derivados de la eritromicina, composiciones que los contienen, uso de los mismos para preparar un medicamento | |
| HUP0004436A2 (hu) | FP agonistákként alkalmazható aromás C16-C20-szubsztituált tetrahidroprosztaglandinok | |
| EA200600694A1 (ru) | Дисульфидные, сульфидные, сульфоксидные и сульфоновые производные циклических сахаров и их применение | |
| AR009145A1 (es) | Compuetos heterociclicos de guanidinilo utiles como agonistas de alfa-2 adrenoreceptores y composiciones farmaceuticas que los comprenden |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |